ArticleHealth economics2021
The impact of medical and recreational marijuana laws on opioid prescribing in employer-sponsored health insurance.
Article in Health economics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- The clouded debate: A systematic review of comparative longitudinal studies examining the impact of recreational cannabis legalization on key public health outcomes.Frontiers in psychiatry · 2022Pooled it
- The association between state cannabis legalization and non-fatal opioid poisonings among adults with employer-sponsored insurance in the United States.Preventive medicine reports · 2026Article
- Association Between Legal Access to Medical Cannabis and Frequency of Non-Medical Prescription Opioid Use Among U.S. Adults.International journal of mental health and addiction · 2025Article
- Association of State Cannabis Legalization With Cannabis Use Disorder and Cannabis Poisoning.JAMA psychiatry · 2025Article
- Do Medical and Recreational Marijuana State Laws Impact Trends in Postoperative Opioid Prescriptions Among Patients Who Have Undergone TJA?Clinical orthopaedics and related research · 2025Article
- The relationship of medical and recreational cannabis laws with opioid misuse and opioid use disorder in the USA: Does it depend on prior history of cannabis use?The International journal on drug policy · 2025Article
- Recreational Cannabis Laws and Fills of Pain Prescriptions in the Privately Insured.Cannabis (Albuquerque, N.M.) · 2025Article
- Characteristics of patients with non-cancer pain and long-term prescription opioid use who have used medical versus recreational marijuana.Journal of cannabis research · 2024Article
- Recreational and Medical Cannabis Legalization and Opioid Prescriptions and Mortality.JAMA health forum · 2024Article
- Adult Medical Cannabinoid Use and Changes in Prescription Controlled Substance Use.Cannabis and cannabinoid research · 2023Article
- Impact of Recreational Cannabis Legalization on Opioid Prescribing and Opioid-Related Hospital Visits in Colorado: an Observational Study.Journal of general internal medicine · 2023Observational
- Association between fatal opioid overdose and state medical cannabis laws in US national survey data, 2000-2011.The International journal on drug policy · 2022Article
- Recreational cannabis laws and opioid-related emergency department visit rates.Health economics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Using data from Truven Health MarketScan Commercial Claims and Encounters Database between 2009 and 2015, we studied the effects of medical and recreational marijuana laws on opioid prescribing in employer-sponsored health insurance. We used a differences-in-differences (DD) approach and found that the implementation of medical marijuana laws (MMLs) and recreational marijuana laws (RMLs) reduced morphine milligram equivalents per enrollee by 7% and 13%, respectively. The reduction associated with MMLs was predominately in people aged 55-64, whereas the reduction associated with RMLs was largely in people aged 35-44 and aged 45-54. Our findings suggest that both MMLs and RMLs have the potential to reduce opioid prescribing in the privately insured population, especially for the middle-aged population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.